ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia
Open Access
- 6 October 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (3) , 310-323
Abstract
Hypophosphatasia (HPP) is caused by loss-of-function mutations in the human ALPL gene that encodes tissue-nonspecific alkaline phosphatase (TNAP), whose deficiency results in the accumulation of the calcification inhibitor inorganic pyrophosphate (PPi), resulting in skeletal and dental hypomineralization. Enzyme replacement with mineral-targeted TNAP (asfotase alfa) improves skeletal mineralization but the almost daily injections of this biologic can lead to injection site reactions and discontinuation of treatment. Since PPi is produced by the enzymatic action of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) from adenosine triphosphate (ATP), we tested if ENPP1 could be a druggable target for the development of an alternative treatment for HPP, particularly for the non-lethal later-onset forms of HPP, where enzyme replacement is not currently approved. We orally administered 30 and 100 mg/kg/day of an ENPP1 inhibitor, REV102, to the AlplPrx1/− mouse model of late-onset HPP, for 105 days and confirmed target engagement, as plasma PPi concentrations were markedly reduced. X-ray, micro-CT, and bone morphometry indicated improvement in appendicular skeletal mineralization. This study suggests that the adult HPP phenotype could benefit from oral administration of ENPP1 inhibitors.Keywords
Funding Information
- Sponsored Research Agreement (CSRA 21-006)
- National Institutes of Health (R01 DE032334)
This publication has 49 references indexed in Scilit:
- Gene Therapy Using Recombinant AAV Type 8 Vector Encoding TNAP‐D10 Improves the Skeletal Phenotypes in Murine Models of OsteomalaciaJBMR Plus, 2022
- Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl−/− MiceJournal of Bone and Mineral Research, 2020
- Inhibition of tissue‐nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD‐MBD mouse modelThe Journal of Pathology, 2019
- Alkaline Phosphatase and HypophosphatasiaCalcified Tissue International, 2015
- Pathophysiological Role of Vascular Smooth Muscle Alkaline Phosphatase in Medial Artery CalcificationJournal of Bone and Mineral Research, 2014
- Ablation of Osteopontin Improves the Skeletal Phenotype of Phospho1 −/− MiceJournal of Bone and Mineral Research, 2014
- In Vivo Overexpression of Tissue-Nonspecific Alkaline Phosphatase Increases Skeletal Mineralization and Affects the Phosphorylation Status of OsteopontinJournal of Bone and Mineral Research, 2013
- Tooth root dentin mineralization defects in a mouse model of hypophosphatasiaJournal of Bone and Mineral Research, 2012
- Enzyme replacement prevents enamel defects in hypophosphatasia miceJournal of Bone and Mineral Research, 2012
- Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: A unified model of the mechanisms of initiation of skeletal calcificationJournal of Bone and Mineral Research, 2011